SCHEMBL3547229

SCHEMBL3547229

CCCc1cc(C(=O)O)cc(OC)c1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.66
CA1 P00915 2/20 0.66
CA2 P00918 2/20 0.66
CA4 P22748 2/20 0.66
CA6 P23280 2/20 0.66
CA7 P43166 2/20 0.66
CA9 Q16790 2/20 0.66
CA14 Q9ULX7 2/20 0.66
CA3 P07451 1/20 0.66
PKM P14618 1/20 0.66
CA5A P35218 1/20 0.66
CA5B Q9Y2D0 1/20 0.66
PTGS2 P35354 5/20 0.62
ALOX5 P09917 5/20 0.50
TPMT P51580 2/20 0.50
HMGCR P04035 1/20 0.49
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.46
PTGS1 P23219 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29279323 0.88 CA12 (0.72) CA12CA1CA2CA4CA6
SCHEMBL3547596 0.86 ALOX5 (0.49) CA12CA1CA2CA4CA6
SCHEMBL28503260 0.84 ALDH1A1 (0.58) CA12CA1CA2CA4CA6
SCHEMBL3546860 0.84 TPMT (0.58) CA12CA1CA2CA4CA6
SCHEMBL13851422 0.83 CA12 (0.70) CA12CA1CA2CA4CA6
Syringic Acid SCHEMBL31550974 0.81 CA12 (0.79) CA12CA1CA2CA4CA6
Syringic Acid SCHEMBL31550982 0.81 CA12 (0.79) CA12CA1CA2CA4CA6
Syringic Acid SCHEMBL27602358 0.80 CA12 (1.00) CA12CA1CA2CA4CA6
Syringic Acid SCHEMBL42751 0.80 CA12 (1.00) CA12CA1CA2CA4CA6
SCHEMBL3547262 0.79 CA12 (0.61) CA12CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE CA12 3880/4885CA1 4363/4885CA2 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.